Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Infectious Diseases Unit, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milano, Italy.
Department of Pathophysiology and Transplantation, University of Milan, Milano, Italy.
J Infect Public Health. 2024 Mar;17(3):467-473. doi: 10.1016/j.jiph.2023.12.026. Epub 2024 Jan 17.
Despite the well-known efficacy of anti-COVID-19 vaccines in preventing morbidity and mortality, several vaccinated individuals are diagnosed with SARS-CoV-2 breakthrough infection, which might require hospitalisation. This multicentre, observational, and retrospective study aimed to investigate the clinical characteristics and outcomes of vaccinated vs. non-vaccinated patients, both hospitalised with SARS-CoV-2 infection in 3 major hospitals in Northern Italy.
Data collection was retrospective, and paper and electronic medical records of adult patients with a diagnosed SARS-CoV-2 infection were pseudo-anonymised and analysed. Vaccinated and non-vaccinated individuals were manually paired, using a predetermined matching criterion (similar age, gender, and date of hospitalisation). Demographic, clinical, treatment, and outcome data were compared between groups differing by vaccination status using Pearson's Chi-square and Mann-Whitney tests. Moreover, multiple logistic regression analyses were performed to assess the impact of vaccination status on ICU admission or intra-hospital mortality.
Data from 360 patients were collected. Vaccinated patients presented with a higher prevalence of relevant comorbidities, like kidney replacement therapy or haematological malignancy, despite a milder clinical presentation at the first evaluation. Non-vaccinated patients required intensive care more often than their vaccinated counterparts (8.8% vs. 1.7%, p = 0.002). Contrariwise, no difference in intra-hospital mortality was observed between the two groups (19% vs. 20%, p = 0.853). These results were confirmed by multivariable logistic regressions, which showed that vaccination was significantly associated with decreased risk of ICU admission (aOR=0.172, 95%CI: 0.039-0.542, p = 0.007), but not of intra-hospital mortality (aOR=0.996, 95%CI: 0.582-1.703, p = 0.987).
This study provides real-world data on vaccinated patients hospitalised with COVID-19 in Northern Italy. Our results suggest that COVID-19 vaccination has a protective role in individuals with higher risk profiles, especially regarding the need for ICU admission. These findings contribute to our understanding of SARS-CoV-2 infection outcomes among vaccinated individuals and emphasise the importance of vaccination in preventing severe disease, particularly in those countries with lower first-booster uptake rates.
尽管抗新冠病毒疫苗在预防发病和死亡方面具有显著疗效,但仍有部分已接种疫苗的个体被诊断出患有新冠病毒突破感染,这可能需要住院治疗。这项多中心、观察性、回顾性研究旨在调查意大利北部 3 家主要医院中因新冠病毒感染住院的接种组和未接种组患者的临床特征和结局。
数据收集为回顾性,对纸质和电子病历中诊断为新冠病毒感染的成年患者数据进行了匿名处理并进行了分析。接种组和未接种组患者使用预先确定的匹配标准(相似年龄、性别和住院日期)进行手动配对。使用 Pearson χ²检验和 Mann-Whitney 检验比较两组之间的人口统计学、临床、治疗和结局数据。此外,还进行了多因素逻辑回归分析,以评估疫苗接种状态对 ICU 入院或院内死亡率的影响。
共收集了 360 名患者的数据。尽管接种组患者的首次评估时临床表现较轻,但他们的合并症发生率更高,如肾脏替代治疗或血液恶性肿瘤。与接种组相比,未接种组患者更常需要入住 ICU(8.8%比 1.7%,p=0.002)。然而,两组之间的院内死亡率无差异(19%比 20%,p=0.853)。多变量逻辑回归也证实了这一结果,表明接种疫苗与 ICU 入院风险降低显著相关(aOR=0.172,95%CI:0.039-0.542,p=0.007),但与院内死亡率无关(aOR=0.996,95%CI:0.582-1.703,p=0.987)。
本研究提供了意大利北部因新冠病毒感染住院的接种患者的真实世界数据。我们的结果表明,新冠病毒疫苗接种在具有更高风险特征的个体中具有保护作用,尤其是在需要入住 ICU 方面。这些发现有助于我们了解接种个体的新冠病毒感染结局,并强调了疫苗接种在预防疾病严重程度方面的重要性,特别是在那些首剂加强针接种率较低的国家。